Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by JLGeminion May 10, 2011 3:25pm

237 Views

Post# 18555612

RE: Another NCI trial starting in the news ....

There is nothing wrong with a Phase 1 trial canrich5. It is a starting point. The important points are that the trial was US NCI's call, and they are picking up the expenses. Except for the cost of supplying Reolysin, this trial is a freebee to shareholders. As indicated in the press release, the US NCI sees this trial as important because current therapies are not effective. Brad listed Oncolytics priorities in the interview that Pericles posted as a “Must Listen.” Multiple Myeloma Cancer trials were not on the list. I share your view that the US NCI is doing the leg work to broaden the base for the application (market) for Reolysin.

As for Cravenraven’s reply, it is his typical defence of the buy side manipulation. There are 38 shopping days until the World Lung Cancer Conference. Brad is driving to commercialization and the partners are not going to wait 2 years. The days of the buy side manipulation are coming to a close. It is great to see the low volumes as retail investors hold onto their shares and buy.

Remember Dendreon’s stock performance in April 2009.

Trading of Dendreon, DNDN, on the NASDAQ

Date	Close	Volume

31-Dec-08	4.58	714,221
15-Jan-09	4.61	2,471,820
30-Jan-09	3.37	1,317,839
17-Feb-09	3.65	1,606,247
27-Feb-09	3.05	2,757,763
16-Mar-09	3.95	4,921,467
31-Mar-09	4.20	2,296,321
01-Apr-09	4.14	3,199,650
02-Apr-09	4.34	2,427,867
03-Apr-09	5.99	22,497,200
06-Apr-09	6.58	19,585,750
07-Apr-09	6.58	7,346,062
08-Apr-09	6.37	5,392,639
09-Apr-09	6.30	4,234,697
13-Apr-09	7.30	12,775,310
14-Apr-09	16.99	65,120,890
15-Apr-09	17.17	19,294,060
16-Apr-09	17.03	6,894,881
17-Apr-09	17.99	17,799,470
20-Apr-09	19.52	17,724,250
21-Apr-09	19.74	11,008,510
22-Apr-09	20.12	7,358,435
23-Apr-09	20.33	6,123,418
24-Apr-09	20.08	7,393,327
27-Apr-09	21.55	18,569,850
28-Apr-09	11.81	28,070,740
29-Apr-09	22.94	48,235,790
30-Apr-09	21.20	17,468,950
Yesterday
09-May-11	39.53	1,807,086